1037 ET - Hims & Hers Health logged heavy revenue gains in 3Q in part from its compounded weight-loss drug business, but the company's core telehealth business looked strong too, Piper Sandler analysts Korinne Wolfmeyer and Sarah Morin say in a research note. Management called out strong demand across the Hers platform, which focuses on women's health and personal care, as well as rising demand for personalized offerings and medications that treat multiple conditions at once, the analysts say. Stripping out the weight-loss business, the company's subscriber count in 3Q was still more than 40% higher year-over-year. (dean.seal@wsj.com)
(END) Dow Jones Newswires
November 05, 2024 10:37 ET (15:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。